EAU 2020: Health-Related Quality-of-Life Analysis From KEYNOTE-426: Pembrolizumab Plus Axitinib vs Sunitinib for Advanced Renal Cell Carcinoma
(UroToday.com) As part of the “Game-changing Session 4” plenary session at the European Association of Urology (EAU) Virtual Annual Meeting, Dr. Bedke discussed health-related quality of life analysis from the KEYNOTE-426 trial. As most UroToday readers will know, the primary analysis of the KEYNOTE-426 trial demonstrated a significant survival advantage for patients with metastatic renal cell carcinoma […]